J&J's Intravenous Remicade Grows Despite Tough Times
This article was originally published in The Pink Sheet Daily
Executive Summary
Implications for anti-TNFs Humira and Enbrel, which tumbled in the first quarter, are unclear.
You may also be interested in...
With New Crohn's Disease Treatment, China's Hutchison MediPharma Seeks Global Co-development Partner
BEIJING - After reporting "encouraging results" in clinical trials in the U.S. on Crohn's Disease patients treated with an innovative drug developed by the Shanghai-based Hutchison MediPharma, the outfit's chief executive officer said she is seeking a co-development deal with a global partner
With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results
The drug maker also reports rising sales for its dyslipidemia franchise.
With Strong Humira Sales Growth, Abbott Is Bullish On Its Second-Quarter Results
The drug maker also reports rising sales for its dyslipidemia franchise.